NuvoAir’s respiratory platform is designed to allow patients to assess lung function in their own homes and respond to specific symptom questionnaires. The data collected by the platform helps the patient understand their progress and can be shared with their medical team in real-time, according to the company. Doctors and physiotherapists can use that data to predict the worsening of the disease, enabling them to focus on the most critical cases and improve their workflow.
The partnership aims to reduce the frequency of hospital visits, which in turn could reduce the chance of contracting infections, such as chronic lung infections that are common in cystic fibrosis patients.
“We are honored to partner with Roche,” NuvoAir founder & CEO Lorenzo Consoli said in a news release. “We are working with many CF centers across Europe, but never in partnership with a pharmaceutical company. Roche Italy is showing that it wants to position the customer at the center of its strategy and to think holistically about the customer experience. Thanks to Roche Italy, CF patients in Italy will now be able to benefit from a solution that helps them improve the management of their disease.”
“We are delighted to begin this partnership with NuvoAir,” added Roche Italy’s Elia Ganzi. “NuvoAir has designed an excellent respiratory platform that truly has the potential to deliver concrete medical advancements to CF patients during their disease path and optimize workflow for the medical team. This partnership is very strategic for us, with a view to promoting an open innovation path that makes Roche more and more a supplier of integrated healthcare solutions and not just drugs.”